Secreted autotransporter toxin produced by probiotic Escherichia coli Nissle 1917 enhances neurodegeneration in Caenorhabditis elegans.

microPublication biology Pub Date : 2025-01-30 eCollection Date: 2025-01-01 DOI:10.17912/micropub.biology.001366
Graham Redweik, Ding Xue
{"title":"Secreted autotransporter toxin produced by probiotic <i>Escherichia coli</i> Nissle 1917 enhances neurodegeneration in <i>Caenorhabditis elegans</i>.","authors":"Graham Redweik, Ding Xue","doi":"10.17912/micropub.biology.001366","DOIUrl":null,"url":null,"abstract":"<p><p>First isolated during World War I, <i>Escherichia coli</i> Nissle 1917 (ECN) is an intensively studied bacterium that produces several factors that can inhibit pathogenic bacteria to promote gut health. These findings have led to its commercialization as a probiotic bacterium widely available for human consumption. Notably, the genome of ECN is highly analogous to many extraintestinal pathogenic <i>E. coli</i> (ExPEC) strains that do cause diseases in humans. Both ECN and ExPEC carry the <i>sat</i> gene which encodes a cytotoxic serine autotransporter toxin (Sat). Given that the role of ECN Sat in human disease has been poorly studied, we sought to implement the nematode <i>C. elegans</i> as a model for analyzing how ECN Sat may impact human neurodegenerative disease. Using multiple <i>C. elegans</i> disease models, we find that ECN Sat induces significantly higher neurodegeneration in several <i>C. elegans</i> models we tested. Although preliminary, our early findings suggest that careful studies are paramount to assess the impact of ECN to humans susceptible of neurodegenerative disease to determine the long-term safety of ECN as a commercial probiotic.</p>","PeriodicalId":74192,"journal":{"name":"microPublication biology","volume":"2025 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822469/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"microPublication biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17912/micropub.biology.001366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

First isolated during World War I, Escherichia coli Nissle 1917 (ECN) is an intensively studied bacterium that produces several factors that can inhibit pathogenic bacteria to promote gut health. These findings have led to its commercialization as a probiotic bacterium widely available for human consumption. Notably, the genome of ECN is highly analogous to many extraintestinal pathogenic E. coli (ExPEC) strains that do cause diseases in humans. Both ECN and ExPEC carry the sat gene which encodes a cytotoxic serine autotransporter toxin (Sat). Given that the role of ECN Sat in human disease has been poorly studied, we sought to implement the nematode C. elegans as a model for analyzing how ECN Sat may impact human neurodegenerative disease. Using multiple C. elegans disease models, we find that ECN Sat induces significantly higher neurodegeneration in several C. elegans models we tested. Although preliminary, our early findings suggest that careful studies are paramount to assess the impact of ECN to humans susceptible of neurodegenerative disease to determine the long-term safety of ECN as a commercial probiotic.

求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
3 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信